Quick Answer
ADIAL PHARMACEUTICALS, INC. reported Operating Income Loss of -$7.80 million for the year ending 2025.
- ADIAL PHARMACEUTICALS, INC. showed an increase of +5.9% in Operating Income Loss from 2024 to 2025.
- This data is from ADIAL PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), ADIAL PHARMACEUTICALS, INC.'s Operating Income Loss has declined by 683.6%.
- Historical annual values: Fiscal year 2025: -$7.80 million | Fiscal year 2024: -$8.28 million | Fiscal year 2023: -$6.89 million | Fiscal year 2022: -$10.86 million | Fiscal year 2021: -$19.29 million | Fiscal year 2020: -$10.93 million | Fiscal year 2019: -$8.24 million | Fiscal year 2018: -$6.99 million | Fiscal year 2017: -$995.3 thousand.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: